For the risk-averse, buy shares on weakness before the seasonally strong fourth quarter. Lesa Sroufe, Ragen MacKenzie. Andrew Heyward, Ragen MacKenzie. Losses increase, but that's not critical for a developmental-stage company such as this. Investors need a long-term focus.
Opportunity justifies rich price.
Andrew Heyward, Ragen MacKenzie. Stock price remains linked to the progress of Icos' erectile-dysfunction drug. Jonathan Geurkink, Ragen MacKenzie. Cash position remains comfortable. Andrew Heyward, Ragen MacKenzie.